ly3454738
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 29, 2018 (NCT03750643)
Timeline
Indications
Mechanism of action
CD200R1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06173895 | Phase 1 | Jan 9, 2024 | Eli Lilly |
| NCT05911841 | Phase 2 | Jun 21, 2023 | Eli Lilly |
| NCT04159701 | Phase 2 | Nov 15, 2019 | Eli Lilly |
| NCT03750643 | Phase 1 | Nov 29, 2018 | Eli Lilly |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 4 | 4 | 2 | 2018 |
1 organizations
Page 1 / 1